BRCAwt and BRCA1 vs. BRCA2), considering different BC recurrence risks and, according to age at diagnosis, addressing questionable risk-reducing effects in older (> 50 years) patients [2, 25, 28–30]. This evidence concerns the gene BRCA2 and breast cancer.